04Jun 2023
Capivasertib in Hormone Receptor–Positive Advanced Breast Cancer

Capivasertib in Hormone Receptor–Positive Advanced Breast Cancer

The study evaluated the efficacy and safety of capivasertib, an AKT inhibitor, in combination with fulvestrant therapy for hormone receptor-positive advanced breast cancer patients. The capivasertib-fulvestrant combination therapy showed a median progression-free survival of 7.2 months compared to 3.6 months in the placebo-fulvestrant group. Among patients with AKT pathway alterations, the median progression-free survival was 7.3 months in the capivasertib-fulvestrant group compared to 3.1 months in the placebo-fulvestrant group. Adverse events such as rash and diarrhea were observed in the capivasertib group. These findings suggest that capivasertib, in combination with fulvestrant, extends progression-free survival in hormone receptor-positive advanced breast cancer patients, especially those with AKT pathway alterations.

  • #family health

Like

Save

Share